BIOTRICITY INC. (OTCMKTS:BTCY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Entry into a Material Definitive Agreement.

On December 22, 2017, Biotricity Inc. (the “Company”) entered into a definitive securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”) set forth on the pages of the Purchase Agreement for the purchase and sale of an aggregate of 450,164 shares of the Company’s common stock in a registered direct offering for gross proceeds of $2,475,901. The registered direct offering also closed on December 22, 2017 and the purchase price paid by the Purchasers was $5.50 per share. The form of Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form8-K.

The net proceeds to the Company from the offering, after deducting estimated offering expenses, are approximately $2.4 million.

The 450,164 shares of common stock were offered, and issued, to the Prospectus Supplement, dated December 22, 2017, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No.333-222065) filed with the Securities and Exchange Commission on December 19, 2017.

The foregoing summary of the terms of the Purchase Agreement described herein is subject to, and qualified in its entirety by, such document, which is incorporated herein by reference.

The opinion delivered to the Company by Sichenzia Ross Ference Kesner LLP in connection with the sale of an aggregate of 450,164 shares of the Company’s common stock to the Purchase Agreement is being filed herewith in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act of 1933 and is incorporated by reference into the Company’s Registration Statement on Form S-3 (Registration No. 333-222065).

BIOTRICITY INC. Exhibit
EX-99.1 2 f991.htm PRESS RELEASE Converted by EDGARwiz Biotricity Closes a Registered Direct Financing and Paves the Way for Bioflux Launch Biotricity Completes Financing with Existing Investors in Anticipation of Bioflux Launch and Sales Force Build-Out REDWOOD CITY,…
To view the full exhibit click here

About BIOTRICITY INC. (OTCMKTS:BTCY)

Biotricity Inc is a Canada-based medical technology company. The Company delivers remote biometric monitoring solutions, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. It offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases or coronary heart diseases, acts as an ambulatory monitor that detects arrhythmias, performs remote mobile cardiac telemetry diagnostic monitoring, and transmits ECG data via a built-in cellular radio in real time. The Company also provides biolife, a health and lifestyle solution for individuals, which consists of a device that monitors heart-rhythm or ECG, as well as respiration, calories, temperature, physical activity, and other.